Outcomes with trastuzumab deruxtecan by biomarker status, line of treatment and prior receipt of sacituzumab govitecan in a large real-world database of patients with metastatic breast cancer
In a large dataset, T-DXd showed favorable activity for treating MBC, although outcomes for HER2-positive disease appeared worse than those observed in clinical trials. Prior SG treatment was associated with inferior outcomes with T-DXd, suggesting cross-resistance between these antibody-drug conjugates.
Authors
- Julia Foldi (ORCID: https://orcid.org/0000-0002-7504-867X)
- Sarah Sammons (ORCID: https://orcid.org/0000-0003-2589-9422)
- Thomas Grinda (ORCID: https://orcid.org/0000-0002-8567-9627)
- Ian E. Krop (ORCID: https://orcid.org/0000-0002-6380-5944)
- Nancy U. Lin (ORCID: https://orcid.org/0000-0003-2263-5413)
- Sara M. Tolaney (ORCID: https://orcid.org/0000-0002-5940-8671)
- Eric P. Winer (ORCID: https://orcid.org/0000-0002-8819-1723)
- Cary P. Gross (ORCID: https://orcid.org/0000-0002-4974-935X)
- Paolo Tarantino (ORCID: https://orcid.org/0000-0001-8686-0228)
- Maryam B. Lustberg (ORCID: https://orcid.org/0000-0001-8559-5645)
- David Lee (ORCID: https://orcid.org/0000-0003-3346-0970)
- Pamela R. Soulos
Institutions
- University of Pittsburgh (US)
- Yale University (US)
- Dana-Farber Cancer Institute (US)
- Smilow Cancer Hospital (US)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-06-17
- DOI
- https://doi.org/10.1016/j.esmoop.2025.105330
- Citations
- 9
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 9.41